福耀玻璃(03606.HK)李小溪:公司主力生產汽車玻璃 排名全球第一
福耀玻璃(03606.HK)舉行2021年年度業績說明會,被問及公司業績被信義玻璃超越時,其董事會祕書李小溪表示,目前公司主要生產銷售汽車玻璃,全球排名第一;而據福耀玻璃內部數據測算,去年公司在全球汽車玻璃行業市場佔有率近31%。李小溪又稱,祝賀信義玻璃在其所處領域取得的成績。
另外,福耀玻璃今日(22日)在互動平臺表示,俄羅斯工廠目前生產運作正常,俄烏局勢緊張對俄羅斯工廠會有一定的影響,但其收入僅佔集團合併收入約2.5%左右,集團會強化經營管理,減少緊張局勢帶來的不利影響。(ca/a)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.